Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:COGT NASDAQ:HROW NASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.56+15.6%$1.89$1.11▼$5.00$415.18M1.872.25 million shs9.87 million shsCOGTCogent Biosciences$13.25+2.4%$12.10$3.72▼$13.55$1.51B0.351.94 million shs868,683 shsHROWHarrow$47.88-2.0%$38.05$20.85▼$59.23$1.77B0.33494,866 shs496,497 shsJANXJanux Therapeutics$22.84-0.6%$24.34$21.97▼$71.71$1.37B2.84908,808 shs837,690 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-2.17%+2.27%-22.86%-41.81%-61.43%COGTCogent Biosciences+3.44%+3.19%+6.77%+83.03%+21.50%HROWHarrow+5.99%+13.92%+24.87%+54.83%+9.92%JANXJanux Therapeutics-2.25%-1.84%-5.43%-1.12%-54.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.56+15.6%$1.89$1.11▼$5.00$415.18M1.872.25 million shs9.87 million shsCOGTCogent Biosciences$13.25+2.4%$12.10$3.72▼$13.55$1.51B0.351.94 million shs868,683 shsHROWHarrow$47.88-2.0%$38.05$20.85▼$59.23$1.77B0.33494,866 shs496,497 shsJANXJanux Therapeutics$22.84-0.6%$24.34$21.97▼$71.71$1.37B2.84908,808 shs837,690 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-2.17%+2.27%-22.86%-41.81%-61.43%COGTCogent Biosciences+3.44%+3.19%+6.77%+83.03%+21.50%HROWHarrow+5.99%+13.92%+24.87%+54.83%+9.92%JANXJanux Therapeutics-2.25%-1.84%-5.43%-1.12%-54.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.12484.62% UpsideCOGTCogent Biosciences 2.92Moderate Buy$20.0050.94% UpsideHROWHarrow 2.88Moderate Buy$65.3336.45% UpsideJANXJanux Therapeutics 3.06Buy$78.31242.85% UpsideCurrent Analyst Ratings BreakdownLatest AUTL, HROW, JANX, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/24/2025AUTLAutolus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform9/24/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.009/23/2025HROWHarrowB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $70.009/23/2025HROWHarrowCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $64.009/17/2025JANXJanux TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$47.009/16/2025JANXJanux TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$47.009/12/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/10/2025JANXJanux TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$100.009/10/2025JANXJanux TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.009/3/2025JANXJanux TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.009/3/2025JANXJanux TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$10.12M41.03N/AN/A$1.61 per share0.97COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/AHROWHarrow$199.61M8.88$0.14 per share337.06$1.95 per share24.55JANXJanux Therapeutics$439K3,126.53N/AN/A$19.49 per share1.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)COGTCogent Biosciences-$255.86M-$1.78N/AN/AN/AN/A-223.82%-89.44%11/11/2025 (Estimated)HROWHarrow-$17.48M-$0.25N/A119.70N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)Latest AUTL, HROW, JANX, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 million8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A8/5/2025Q2 2025COGTCogent Biosciences-$0.55-$0.53+$0.02-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A8.438.07COGTCogent BiosciencesN/A4.194.19HROWHarrow0.780.620.58JANXJanux TherapeuticsN/A47.0347.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%COGTCogent BiosciencesN/AHROWHarrow72.76%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%COGTCogent Biosciences7.29%HROWHarrow13.67%JANXJanux Therapeutics29.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableHROWHarrow18037.00 million31.94 millionOptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableAUTL, HROW, JANX, and COGT HeadlinesRecent News About These CompaniesJanux Therapeutics (NASDAQ:JANX) Raised to Strong-Buy at BarclaysSeptember 19, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up - Here's WhySeptember 18, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Now Covered by BarclaysSeptember 18, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at BarclaysSeptember 18, 2025 | americanbankingnews.comBarclays Initiates Coverage of Janux Therapeutics (JANX) with Overweight RecommendationSeptember 17, 2025 | msn.comJanux Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comGoldman Sachs Group Inc. Has $7.73 Million Stock Holdings in Janux Therapeutics, Inc. $JANXSeptember 16, 2025 | marketbeat.comTruist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PTSeptember 15, 2025 | msn.comFinancial Survey: Werewolf Therapeutics (NASDAQ:HOWL) & Janux Therapeutics (NASDAQ:JANX)September 13, 2025 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Now Covered by Truist FinancialSeptember 12, 2025 | marketbeat.comStifel Nicolaus Reaffirms Buy Rating for Janux Therapeutics (NASDAQ:JANX)September 12, 2025 | marketbeat.comWoodline Partners LP Sells 395,092 Shares of Janux Therapeutics, Inc. $JANXSeptember 12, 2025 | marketbeat.comJanux Therapeutics initiated with a Buy at TruistSeptember 11, 2025 | msn.comTruist Securities Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationSeptember 11, 2025 | msn.comJanux Therapeutics resumed with a Buy at StifelSeptember 10, 2025 | msn.comJanux is a new Buy at Truist ahead of catalyst rich H2September 10, 2025 | msn.comCubist Systematic Strategies LLC Buys 35,511 Shares of Janux Therapeutics, Inc. $JANXSeptember 9, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Now Covered by GuggenheimSeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Acquires 63,762 Shares of Janux Therapeutics, Inc. $JANXSeptember 7, 2025 | marketbeat.comWalleye Capital LLC Invests $307,000 in Janux Therapeutics, Inc. $JANXSeptember 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUTL, HROW, JANX, and COGT Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.56 +0.21 (+15.56%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Cogent Biosciences NASDAQ:COGT$13.25 +0.31 (+2.40%) Closing price 04:00 PM EasternExtended Trading$13.26 +0.01 (+0.04%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Harrow NASDAQ:HROW$47.88 -0.97 (-1.99%) Closing price 04:00 PM EasternExtended Trading$48.82 +0.94 (+1.96%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Janux Therapeutics NASDAQ:JANX$22.84 -0.14 (-0.61%) Closing price 04:00 PM EasternExtended Trading$23.02 +0.18 (+0.77%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Broadcom Price Targets Just Reached Above $400 for the First Time Replace Your Fixed Income With This Dividend ETF These 3 Mega-Cap Giants Just Increased Dividends by 7% or More Ford Set to Outpace GM With Tariff Tailwinds and EPS Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
